These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29884903)

  • 1. Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.
    Tasian SK; Casas JA; Posocco D; Gandre-Babbe S; Gagne AL; Liang G; Loh ML; Weiss MJ; French DL; Chou ST
    Leukemia; 2019 Jan; 33(1):181-190. PubMed ID: 29884903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia.
    Shigemura T; Matsuda K; Kurata T; Sakashita K; Okuno Y; Muramatsu H; Yue F; Ebihara Y; Tsuji K; Sasaki K; Nakahata T; Nakazawa Y; Koike K
    Br J Haematol; 2019 Oct; 187(2):163-173. PubMed ID: 31222725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia.
    Gandre-Babbe S; Paluru P; Aribeana C; Chou ST; Bresolin S; Lu L; Sullivan SK; Tasian SK; Weng J; Favre H; Choi JK; French DL; Loh ML; Weiss MJ
    Blood; 2013 Jun; 121(24):4925-9. PubMed ID: 23620576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL.
    Gagne AL; Maguire JA; Gandre-Babbe S; Chou ST; Tasian SK; Loh ML; Weiss MJ; Gadue P; French DL
    Stem Cell Res; 2018 Aug; 31():157-160. PubMed ID: 30096712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
    Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
    Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.
    Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia.
    Pearson S; Guo B; Pierce A; Azadbakht N; Brazzatti JA; Patassini S; Mulero-Navarro S; Meyer S; Flotho C; Gelb BD; Whetton AD
    J Proteome Res; 2020 Jan; 19(1):194-203. PubMed ID: 31657576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
    Mulero-Navarro S; Sevilla A; Roman AC; Lee DF; D'Souza SL; Pardo S; Riess I; Su J; Cohen N; Schaniel C; Rodriguez NA; Baccarini A; Brown BD; Cavé H; Caye A; Strullu M; Yalcin S; Park CY; Dhandapany PS; Yongchao G; Edelmann L; Bahieg S; Raynal P; Flex E; Tartaglia M; Moore KA; Lemischka IR; Gelb BD
    Cell Rep; 2015 Oct; 13(3):504-515. PubMed ID: 26456833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
    Tarnawsky SP; Yoshimoto M; Deng L; Chan RJ; Yoder MC
    Dev Dyn; 2017 Dec; 246(12):1001-1014. PubMed ID: 28975680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway.
    Bunda S; Qin K; Kommaraju K; Heir P; Ohh M
    Oncogene; 2015 Feb; 34(6):789-97. PubMed ID: 24469048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.
    Jenkins C; Luty SB; Maxson JE; Eide CA; Abel ML; Togiai C; Nemecek ER; Bottomly D; McWeeney SK; Wilmot B; Loriaux M; Chang BH; Tyner JW
    Sci Signal; 2018 Jul; 11(539):. PubMed ID: 30018082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated molecular profiling of juvenile myelomonocytic leukemia.
    Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
    Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LNK/
    Wintering A; Hecht A; Meyer J; Wong EB; Hübner J; Abelson S; Feldman K; Kennedy VE; Peretz CAC; French DL; Maguire JA; Jobaliya C; Vasquez MR; Desai S; Dulman R; Nemecek E; Haines H; Hammad M; El Haddad A; Kogan SC; Abdullaev Z; Chehab FF; Tasian SK; Smith CC; Loh ML; Stieglitz E
    Haematologica; 2024 Aug; 109(8):2533-2541. PubMed ID: 38152053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induced Pluripotent Stem Cells to Model Juvenile Myelomonocytic Leukemia: New Perspectives for Preclinical Research.
    Wehbe Z; Ghanjati F; Flotho C
    Cells; 2021 Sep; 10(9):. PubMed ID: 34571984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.
    Javadi M; Richmond TD; Huang K; Barber DL
    J Biol Chem; 2013 Jul; 288(27):19459-70. PubMed ID: 23696637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.
    Loh ML; Sakai DS; Flotho C; Kang M; Fliegauf M; Archambeault S; Mullighan CG; Chen L; Bergstraesser E; Bueso-Ramos CE; Emanuel PD; Hasle H; Issa JP; van den Heuvel-Eibrink MM; Locatelli F; Stary J; Trebo M; Wlodarski M; Zecca M; Shannon KM; Niemeyer CM
    Blood; 2009 Aug; 114(9):1859-63. PubMed ID: 19571318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Juvenile myelomonocytic leukemias].
    Lachenaud J; Strullu M; Baruchel A; Cavé H
    Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
    Sakashita K
    Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JMML genomics and decisions.
    Niemeyer CM
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):307-312. PubMed ID: 30504325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
    Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK
    J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.